Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
5-Amino-1MQ vs. Tirzepatide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
5-Amino-1MQ is distinguished by 5-Amino-1MQ is a small-molecule enzyme inhibitor—not a peptide, receptor agonist, NAD+ product, or nicotinamide precursor; Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
5-Amino-1MQ is distinguished in the current record by 5-Amino-1MQ is a small-molecule enzyme inhibitor—not a peptide, receptor agonist, NAD+ product, or nicotinamide precursor. Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceTirzepatide
5-Amino-1MQ: Preclinical evidence only. Tirzepatide: Mature human evidence.
Regulatory historyTirzepatide
5-Amino-1MQ: Not FDA approved. Tirzepatide: FDA approved for defined indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
5-Amino-1MQ
- Body weight and adiposity in obese mice
- Glucose tolerance and insulin sensitivity in mice
- Fatty liver and metabolic dysfunction in mice
- Aged muscle regeneration and strength in mice
Tirzepatide
- Obesity
- Type 2 diabetes
- Cardiometabolic outcomes
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
5-Amino-1MQNot FDA approved
Not FDA approved. FDA stated in a January 2026 warning letter that 5-amino-1-methylquinolinium iodide was not eligible for 503B compounding under the circumstances described.
TirzepatideFDA-labeled indications
FDA approved as Mounjaro for type 2 diabetes and Zepbound for defined adult weight-management and OSA indications.
Evidence depthEvidence, not a winner
5-Amino-1MQCells + mice only
Repeated adipocyte and mouse metabolic findings, two aged-mouse muscle studies, a cancer-cell study, and a bladder-cancer mouse model. Human tumor profiling studied NNMT biology, not 5-Amino-1MQ treatment.
TirzepatideMature Phase 3
Multiple large Phase 3 trials, active-comparator studies, 176-week follow-up, a 13,299-participant cardiovascular outcomes trial, and newer 2026 maintenance data.
Weight outcomesEvidence, not a winner
5-Amino-1MQMouse signal only
Two diet-induced-obesity mouse studies reported lower body weight or weight gain and less fat mass without lower food intake. No human weight-loss evidence was located.
TirzepatidePeer-reviewed Phase 3
SURMOUNT-1 peer-reviewed trial: mean change −15.0%, −19.5%, and −20.9% across studied doses versus −3.1% placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
5-Amino-1MQMouse signal only
A 28-day mouse study reported better glucose tolerance, insulin sensitivity, and hyperinsulinemia measures. No human diabetes-efficacy evidence was located.
TirzepatideApproved + Phase 3
Extensive SURPASS program and FDA approval. SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in type 2 diabetes.
Obstructive sleep apnoeaEvidence, not a winner
5-Amino-1MQNo dedicated evidence
No controlled human or dedicated preclinical obstructive-sleep-apnoea evidence was located.
TirzepatideApproved + Phase 3
Two peer-reviewed Phase 3 trials support the FDA-approved Zepbound indication for moderate-to-severe OSA in adults with obesity.
Cardiovascular outcomesEvidence, not a winner
5-Amino-1MQNo outcomes evidence
No human cardiovascular-outcomes program was located. Mouse metabolic markers are not cardiovascular event evidence.
TirzepatideCVOT + HFpEF trial
SURPASS-CVOT found tirzepatide noninferior—but not superior—to dulaglutide for major cardiovascular events. In SUMMIT, a separate placebo-controlled HFpEF-and-obesity population had fewer composite cardiovascular-death or worsening-heart-failure events; that finding is population-specific.
Administration and handlingEvidence, not a winner
5-Amino-1MQAnimal protocols only
Published animal studies used different subcutaneous, oral, and intravenous exposures. Poor oral bioavailability was reported in mice; no human route, dose, cycle, reconstitution, or storage standard exists.
TirzepatideOfficial FDA label
FDA labels provide product-specific once-weekly subcutaneous dosing and handling. Approved presentations are solutions; no reconstitution is required.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Human pharmacokinetics, safety, tolerability, interactions, dose-response, and whether any mouse metabolic or muscle signal translates into clinical benefit.
- Long-term individual durability and rare events, plus evidence for uses outside studied and approved populations.
Community Intelligence
Emerging patterns, clearly separated from evidence
5-Amino-1MQ
No community experiences yetBe the first account holder to contribute.
Tirzepatide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.